A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary
stenting due to acute myocardial infarction.
The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo
coronary artery stenting due to NSTEMI or STEMI will be included.
Primary endpoint (variable):
The composite of cardiac death, spontaneous myocardial infarction or definite or probable
stent thrombosis within 3 months.